Ameritas Investment Partners’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $296K | Buy |
11,699
+1,301
| +13% | +$28.6K | 0.01% | 1148 |
|
|
2026
Q1 | $231K | Hold |
10,398
| – | – | 0.01% | 1184 |
|
|
2025
Q4 | $278K | Hold |
10,398
| – | – | 0.01% | 1064 |
|
|
2025
Q3 | $222K | Sell |
10,398
-2,121
| -17% | -$50.2K | 0.01% | 1181 |
|
|
2025
Q2 | $270K | Hold |
12,519
| – | – | 0.01% | 1132 |
|
|
2025
Q1 | $208K | Hold |
12,519
| – | – | 0.01% | 1240 |
|
|
2024
Q4 | $230K | Buy |
12,519
+795
| +7% | +$12.8K | 0.01% | 1241 |
|
|
2024
Q3 | $180K | Hold |
11,724
| – | – | 0.01% | 1390 |
|
|
2024
Q2 | $191K | Sell |
11,724
-820
| -7% | -$13.2K | 0.01% | 1299 |
|
|
2024
Q1 | $232K | Hold |
12,544
| – | – | 0.01% | 1190 |
|
|
2023
Q4 | $393K | Buy |
12,544
+504
| +4% | +$12K | 0.01% | 892 |
|
|
2023
Q3 | $251K | Buy |
12,040
+2,033
| +20% | +$55.2K | 0.01% | 1044 |
|
|
2023
Q2 | $240K | Buy |
10,007
+623
| +7% | +$13.8K | 0.01% | 1025 |
|
|
2023
Q1 | $177K | Hold |
9,384
| – | – | 0.01% | 1175 |
|
|
2022
Q4 | $179K | Hold |
9,384
| – | – | 0.01% | 1209 |
|
|
2022
Q3 | $153K | Hold |
9,384
| – | – | 0.01% | 1205 |
|
|
2022
Q2 | $132K | Hold |
9,384
| – | – | 0.01% | 1310 |
|
|
2022
Q1 | $227K | Hold |
9,384
| – | – | 0.01% | 1108 |
|
|
2021
Q4 | $219K | Hold |
9,384
| – | – | 0.01% | 1170 |
|
|
2021
Q3 | $156K | Hold |
9,384
| – | – | 0.01% | 1394 |
|
|
2021
Q2 | $229K | Buy |
+9,384
| New | +$212K | 0.01% | 1143 |
|
|
2020
Q2 | – | Sell |
-9,809
| Closed | -$414K | – | 3056 |
|
|
2020
Q1 | $414K | Buy |
9,809
+134
| +1% | +$5.52K | 0.02% | 679 |
|
|
2019
Q4 | $414K | Buy |
9,675
+738
| +8% | +$32.1K | 0.02% | 797 |
|
|
2019
Q3 | $322K | Hold |
8,937
| – | – | 0.01% | 857 |
|
|
2019
Q2 | $239K | Sell |
8,937
-403
| -4% | -$10.3K | 0.01% | 975 |
|
|
2019
Q1 | $251K | Buy |
9,340
+1,216
| +15% | +$28.4K | 0.01% | 935 |
|
|
2018
Q4 | $131K | Hold |
8,124
| – | – | 0.01% | 1205 |
|
|
2018
Q3 | $169K | Hold |
8,124
| – | – | 0.01% | 1200 |
|
|
2018
Q2 | $124K | Buy |
+8,124
| New | +$145K | 0.01% | 1385 |
|
|
2016
Q1 | – | Sell |
-6,151
| Closed | -$219K | – | 1172 |
|
|
2015
Q4 | $219K | Hold |
6,151
| – | – | 0.01% | 899 |
|
|
2015
Q3 | $203K | Hold |
6,151
| – | – | 0.01% | 921 |
|
|
2015
Q2 | $258K | Sell |
6,151
-909
| -13% | -$35.2K | 0.02% | 873 |
|
|
2015
Q1 | $230K | Hold |
7,060
| – | – | 0.02% | 953 |
|
|
2014
Q4 | $224K | Buy |
+7,060
| New | +$200K | 0.02% | 939 |
|
Other funds holding ACAD
BBA
RI
PAI
Ameritas Investment Partners's ACAD Position: Q2 2026 in Review
Ameritas Investment Partners increased its Acadia Pharmaceuticals (ACAD) stake by 13% in Q2 2026, buying an estimated $28.6K and bringing the position to 11,699 shares worth $296K. The position accounts for 0.01% of the portfolio, ranked #1148.
Ameritas Investment Partners first reported a position in ACAD in Q4 2014 and has held it in 34 quarters since. The position peaked at $414K in Q1 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- Ameritas Investment Partners held 11,699 shares of Acadia Pharmaceuticals worth $296K as of Q2 2026.
- Ameritas Investment Partners bought 1,301 Acadia Pharmaceuticals shares in Q2 2026, an estimated $28.6K.
- Acadia Pharmaceuticals made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1148 holding.
- Ameritas Investment Partners first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 34 quarters since.
- Ameritas Investment Partners's Acadia Pharmaceuticals position peaked at $414K in Q1 2020.
- 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.